Genprex (GNPX) said Monday that it has completed the phase 1 dose escalation portion of a trial of Reqorsa gene therapy in combination with Tecentriq to treat extensive stage small cell lung cancer.
The company also said the Safety Review Committee has approved initiating the phase 2 expansion part of the trial.
Shares of Genprex were down 7% in recent trading.
Price: 1.10, Change: -0.07, Percent Change: -5.60
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。